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Effective control of HIV-1 infection in humans is achieved using
combinations of antiretroviral therapy (ART) drugs. In humanized
mice (hu-mice), control of viremia can be achieved using either ART
or by immunotherapy using combinations of broadly neutralizing
antibodies (bNAbs). Here we show that treatment of HIV-1–
infected hu-mice with a combination of three highly potent bNAbs
not only resulted in complete viremic control but also led to a re-
duction in cell-associated HIV-1 DNA. Moreover, lowering the ini-
tial viral load by coadministration of ART and immunotherapy
enabled prolonged viremic control by a single bNAb after ART
was withdrawn. Similarly, a single injection of adeno-associated
virus directing expression of one bNAb produced durable viremic
control after ART was terminated. We conclude that immunother-
apy reduces plasma viral load and cell-associated HIV-1 DNA and
that decreasing the initial viral load enables single bNAbs to con-
trol viremia in hu-mice.
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Antiretroviral therapy (ART) suppresses HIV-1 viremia tonearly undetectable levels within 12–48 wk in a majority of
infected individuals (1, 2). This form of therapy combines at least
three drugs, each of which can target a unique step in the viral
life cycle including reverse transcription, integration, proteolytic
processing, and viral entry (3). However, treatment must be
continued indeﬁnitely because ART interruption leads to rapid
viremic rebound (4, 5), and attempts at treatment intensiﬁcation
by additional drugs have not improved viremic control (6, 7).
Moreover, therapy is associated with a number of side effects
and emergence of resistance, highlighting the need to explore
new therapeutic modalities against HIV-1 (3).
Human monoclonal antibodies to HIV-1 can neutralize a
broad range of viral isolates in vitro and can protect nonhuman
primates against infection (8–10). In contrast, experiments in
humanized mice (hu-mice) and humans initially suggested that
antibodies were unable to control established HIV-1 infection
(11–13). However, advances in single-cell antibody cloning (14–
16) and structure-based design methods (17) uncovered far more
potent antibodies (17–22) that were shown to suppress viremia in
hu-mice (23, 24). Antibodies exhibiting this level of potency and
breadth are rare among infected individuals (25) and typically
arise only 2–3 y after initial infection (26, 27). These antibodies
are extensively somatically mutated (14, 18, 20, 23, 28, 29), and
all efforts to date to elicit them by immunization have failed (15,
30). In contrast to ART, which has no appreciable efﬁcacy after
termination of treatment, antibodies can control infection in hu-
mice for up to 2 mo after cessation of therapy owing to their long
half-life in vivo (23). However, the ability of highly potent
broadly neutralizing antibodies (bNAbs) to sustain viremic con-
trol after termination of ART remains unknown.
Results
Building on our previous ﬁndings that mixtures of antibodies led
to sustained viremic control (23, 24), we sought to characterize
the extent of viral suppression using an optimized immunother-
apy regimen. We selected three antibodies targeting three differ-
ent epitopes on the gp120 portion of the viral spike: 3BNC117,
a potent CD4 binding site (CD4bs) antibody with a longer half-life
than NIH45-46G54W (45-46G54W) (21) (Fig. S1); PG16, which rec-
ognizes the V1/V2 loop region (22, 31); and 10-1074, an antibody
that targets the base of the V3 stem (19). In two independent
experiments, we treated HIV-1YU2 infected hu-mice 2–3 wk after
infection (23, 32) for 6 wk with combination immunotherapy
(1.0 mg per antibody, twice per week s.c.) (Fig. 1 and Fig. S2).
Viral loads were monitored weekly using one of two different
quantitative reverse-transcriptase PCR assays (Fig. 1 A and B
and Fig. S2). All treated mice exhibited rapid and continuous
plasma viral load suppression during the 6-wk treatment course,
with a majority of mice dropping below the limit of viral load
detection (Fig. 1 A–C and Fig. S2). We conclude that combined
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immunotherapy with 3BNC117, PG16, and 10-1074 is sufﬁcient
to control plasma HIV-1 viremia in hu-mice.
Cell-associated HIV-1 DNA is an additional measure of in-
fection that may be more sensitive than circulating viral load (33,
34). To determine the effects of immunotherapy on cell-associ-
ated HIV-1, we measured total HIV-1 DNA in human lymphoid
cells obtained from the blood by quantitative PCR (Fig. 1 D–F).
The average starting HIV-1 DNA content in circulating lym-
phoid cells was 4.6 log10 DNA copies per 10
6 human cells
(geometric average). Although cellular HIV-1 DNA content
transiently increased in some mice during the treatment course,
all mice had signiﬁcantly reduced levels of cellular HIV-1 DNA
after 6 wk of treatment, with an average reduction of 0.8 log10
DNA copies per 106 cells. Lymphoid tissues showed levels of
viral DNA similar to those found in the blood after therapy (Fig.
S3). Taken together, these data demonstrate that immunother-
apy with 3BNC117, PG16, and 10-1074 successfully controls
HIV-1 infection in hu-mice by reducing both plasma viral RNA
and cell-associated viral DNA.
We next sought to test whether highly potent bNAbs can
prolong suppression of HIV-1 infection in mice treated initially
with ART. As expected from studies in humans (35, 36) and hu-
mice (37), treatment of HIV-1–infected hu-mice with ART alone
(tenofovir disproxil-fumarate, raltegravir, and emtricitabine, daily
by oral gavage) lowered viremia by an average of 2.0 log10 copies
per milliliter after 3 wk, but viral load rebounded to pretreatment
levels shortly after ART was discontinued (Fig. S4). To test
whether immunotherapy could prevent viral rebound after stopping
ART, we treated mice with ART for 3 wk and added a bNAb
mixture (45-46G54W, PG16, and 10-1074, 0.5 mg each, twice weekly
s.c.) 5 d after starting ART (Fig. 2). Immunotherapy was continued
for an additional 4 wk after ART was terminated. In contrast to
mice treated with ART alone (Fig. S4), mice treated with a bNAb
trimix did not exhibit viral rebound upon stopping ART (Fig. 2A).
Although transient low-level viremia (<104 copies per milliliter)
was observed in some mice (4/7), viremia in all cases returned
below the limit of detection in the presence of antibody even after
immunotherapy was stopped (Fig. 2 A and B).
Viral load was monitored for an additional 12 wk after stop-
ping antibody therapy. In all cases, viral loads rebounded to
pretreatment levels only when serum antibody titers were low or
undetectable (Fig. 2B). To test whether viremic control after
stopping ART was in fact due to antibody therapy, we obtained
gp120 sequences from plasma virus that emerged after antibody
titers had dropped. Although some viral clones carried mutations
at sites known to confer resistance to one of the three antibodies
in the trimix, no clones were identiﬁed bearing resistance to all
three antibodies (Fig. 2C). Representative gp120 sequences from
each mouse were tested for resistance to each of the antibodies in
the trimix and to the trimix itself (Fig. 2D). In all cases, the viruses
remained sensitive to neutralization by the trimix, indicating that
antibody therapy was responsible for viremic control after ART
was discontinued. We conclude that immunotherapy with 45-
46G54W, PG16, and 10-1074 protects against viral rebound after
discontinuation of ART.
Immunotherapy with a single bNAb alone is ineffective in
suppressing viremia in hu-mice owing to rapid emergence of
antibody-resistant viral mutants (ref. 23 and Fig. S1). Because
immunotherapy with three antibodies was fully protective against
viral rebound in ART-treated mice, we asked whether single
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Fig. 1. Combination immunotherapy with 3BNC117, PG16, and 10-1074. (A)
Plasma viral loads for HIV-1YU2–infected hu-mice treated with combination
immunotherapy were monitored at regular intervals by quantitative RT-PCR.
Each line represents a single animal. Treatment began at day 0. Antibodies
were administered s.c. at 1.0 mg per antibody, twice per week, for a total of
6 wk. Green line, average viral load for untreated mice (Fig. S4). (B) Fold
change in viral load (shown in A) from the baseline measurement for each
animal. Red line shows the geometric mean viral load change at each time
point. Green line, as above. (C) Combination immunotherapy resulted in
a signiﬁcant drop in viral load in all animals (n = 6) after 6 wk of continuous
treatment (*P < 0.05, Wilcoxon signed rank test, two-tailed). (D) Cell-asso-
ciated HIV-1 DNA per 106 human peripheral blood mononuclear cells (PBMC)
over time. Each line represents a single mouse from the same experiment as
in A–C. (E) Fold change in cell-associated HIV-1 DNA (shown in D) from the
baseline measurement for each animal. Red line shows the geometric mean
change in cell-associated HIV-1 DNA levels at each time point. (F) Combi-
nation immunotherapy resulted in a signiﬁcant drop in cell-associated HIV-1
DNA in all animals after 6 wk of continuous treatment (*P < 0.05, Wilcoxon
signed rank test, two-tailed).
Lo
g 1
0 c
op
ie
s 
m
l-1
 
Ab
-20 0 20 40 60 80 100 120
2
3
4
5
6
7
ART
days
40 60 80 100 120
0.1
1
10
100
1000
40 60 80 100 120
2
3
4
5
6
7
40 60 80 100 120
0.1
1
10
100
1000
40 60 80 100 120
102
103
104
105
106
107
40 60 80 100 120
0.1
1
10
100
1000
40 60 80 100 120
102
103
104
105
106
107
40 60 80 100 120
0.1
1
10
100
1000
40 60 80 100 120
102
103
104
105
106
107
40 60 80 100 120
0.1
1
10
100
1000
40 60 80 100 120
102
103
104
105
106
107
days
A 
C 
D 
PG16 45-46W 10-1074 Tri-mix
0.039 0.012 0.025 0.009
0.037 0.020 0.039 0.015
0.058 0.065 0.063 0.019
0.042 21.884 0.046 0.014
0.285 0.035 0.170 0.041
IC50 (ug/ml)
ID# 406 
ID# 415 
ID# 426 
ID# 428 
ID# 447 
B 
Lo
g 1
0 c
op
ie
s 
m
l-1
 
µg m
l -1 
ID# 406 ID# 415 ID# 426 ID# 428 ID# 447 
ID# 406 
160 332 281 459 
ID# 415 
ID# 426 
ID# 428 
ID# 447 
Gp120 residue 100 200 300 400 500 
Fig. 2. Termination of ART in the presence of combined immunotherapy.
(A) Plasma viral loads. HIV-1YU2–infected hu-mice were treated with ART
beginning at day 0 for a total of 3 wk. Five days after starting ART, mice
were additionally treated with combination immunotherapy using bNAbs
45-46G54W, 10-1074, and PG16 (0.5 mg each twice weekly s.c.). ART was
terminated and combination immunotherapy was continued for an addi-
tional 4 wk, then withdrawn. Each line represents a single mouse; viral load
measurements were taken at the indicated time points (symbols). Blue
shading, ART only; purple shading, overlapping ART and immunotherapy;
pink shading, immunotherapy only. Green line, as in Fig. 1A. (B) Individual
mice from A after antibody therapy was stopped. Each plot shows a single
animal. Blue lines/symbols, plasma viral load; red lines/symbols, gp120-
binding human IgG in plasma. (C) Mutations in gp120 cloned from rebound
viral RNA after antibody withdrawal. Each line represents a single clone; red
and green marks indicate nonsynonymous and synonymous mutations rel-
ative to HIV-1YU2, respectively. (D) TZM-bl neutralization IC50 values for the
indicated bNAbs against pseudovirus carrying representative mutations
found in gp120 clones from C for each indicated animal.
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bNAbs could also protect against viral rebound when viral load
was initially suppressed with the help of ART. We administered
ART and added one of four bNAbs (45-46G54W, 3BNC117, 10-
1074, or PG16) for 3–4 wk then terminated ART and continued
bNAb monotherapy alone (Fig. 3). In contrast to hu-mice re-
ceiving antibody monotherapy alone (ref. 23 and Fig. S1), in-
fection remained controlled in 50–86% of the hu-mice receiving
45-46G54W (8/10), 3BNC117 (4/8), or 10-1074 (6/7) monotherapy
after ART was terminated (Fig. 3). As expected, viremia re-
bounded quickly in mice that did not receive continued bNAb
therapy after stopping ART (Fig. S5). The combination of PG16
plus ART differed from the other antibody monotherapy groups
in that only 20% of the mice (1/5) remained controlled after
ART termination (Fig. 3).
Plasma viremia was monitored for an additional 11–13 wk
after termination of bNAb monotherapy, or until viral rebound
was observed. Mice that were controlled by bNAb monotherapy
exhibited viremic rebound (>3 × 103 copies per milliliter) after
an average of 30 d for 45-46G54W, 43 d for 3BNC117, 45 d for
10-1074, and 35 d in the one mouse that was controlled by PG16
(Fig. 4). The time to viremic rebound for each treatment group
correlated with antibody half-life, with all mice rebounding when
serum antibody levels were low or undetectable (Fig. 4 and ref.
23). Three out of 17 mice failed to rebound after antibody levels
became undetectable, indicating that prolonged viremic control
was primarily due to the long half-life of the antibodies. We
conclude that lowering the initial viral load with combined ART
and immunotherapy facilitates viremic control by subsequent
bNAb monotherapy alone in hu-mice.
To determine whether viral escape from antibody mono-
therapy was due to speciﬁc mutations in the HIV-1 envelope
glycoprotein gene (env), we cloned and sequenced gp120 from
HIV-1YU2–infected mice that rebounded during (Fig. 5A) or
after (Fig. 5B) bNAb immunotherapy. Sequences cloned from mice
that rebounded during antibody therapy always carried speciﬁc
mutations in the antibody target sites, and these mutations
rendered them antibody-resistant (Fig. 5A and Figs. S6 and
S7). For example, escape from 45-46G54W and 10-1074 was
associated with YU2A281T and YU2N332K, which are resistant to those
respective antibodies (Fig. 5A and Figs. S6 and S7 and ref. 23).
Similarly, mice that escaped 3BNC117 carried resistance
mutations in the CD4bs at positions YU2(279–281) or YU2(458/459)
(Fig. 5A and Figs. S6 and S7 and refs. 17 and 23), and PG16 es-
cape viruses carried mutations at either YU2N160 or YU2T162, which
remove the key N-linked glycosylation site targeted by this an-
tibody (Fig. 5A and Figs. S6 and S7 and refs. 22 and 23). In
contrast, viruses that emerged after immunotherapy was termi-
nated did not contain antibody resistance mutations (with one
exception, ID number 399) and remained sensitive to neutrali-
zation by the antibodies (Fig. 5B and Figs. S7 and S8). Thus,
bNAb monotherapy alone can sustain viremic suppression in hu-
mice when the viral load is initially lowered by combined ART
and immunotherapy.
Adeno-associated virus (AAV) vectors can direct long-term
expression of anti–HIV-1 antibodies at sufﬁciently high levels to
protect macaques from simian-HIV or hu-mice from HIV-1 in-
fection (38, 39). To determine whether administration of anti-
body monotherapy by AAV can also achieve prolonged control
of established HIV-1 infection, we treated mice with combined
ART and AAVs directing the expression of either 3BNC117 or
10-1074. ART treatment interfered with AAV transduction (Fig.
S9), so the viral load was initially lowered by treatment with ART
and soluble biotin-labeled 10-1074 antibody (10-1074:bio, Fig.
6). Hu-mice with viral loads below the limit of detection 12 d
after stopping ART were injected with 2.5 × 1011 genomic copies
of a 10-1074–expressing AAV (AAV10-1074) and passive delivery
of 10-1074:bio was stopped (Fig. 6A). Consistent with the half-
life of 10-1074 (23), 10-1074:bio dropped to undetectable levels
4–7 wk after the last injection (Fig. 6B). However, AAV10-1074
sustained high levels of circulating 10-1074 (ca. 200 mg/mL)
throughout the entire 67-d observation period (Fig. 6B). Of
seven hu-mice treated with AAV10-1074, only one escaped anti-
body monotherapy (ID number 683), whereas the remaining six
mice (86%) were controlled for the duration of the experiment
(Fig. 6). Gp120 sequencing of virus from the mouse that escaped
revealed mutations in the 10-1074 binding site that conferred
resistance to that antibody (Fig. 6 C and D). Similar results were
obtained for mice treated with AAV3BNC117 (Fig. S9). We con-
clude that a single injection of an AAV-encoded bNAb can
durably control viremia in HIV-1–infected hu-mice.
Whereas individual antiretroviral drugs interfere with the
HIV-1 protease, reverse transcriptase, integrase, or viral entry,
antibodies may affect infection by concurrently interfering with
the virus in a number of different ways. For example, antibodies
can block infection by free virions, but they can also direct the
killing of infected cells that express cell surface gp160 or its frag-
ments by antibody-dependent cell-mediated cytotoxicity/antibody-
dependent cell-mediated viral inhibition (ADCC/ADCVI) (40,
41). In addition, antibodies may be able to block synapse forma-
tion and subsequent cell contact-mediated viral transmission (42–
44). To determine whether the antibodies used in this study
can interfere with cell contact-mediated transmission of HIV-
1YU2, we compared their activity in established cell-free and cell
contact-permitting transmission assays (45) in vitro (Fig. S10). All
antibodies blocked cell-free virus transmission at the expected
concentrations. In addition, the bNAbs 45-46G54W, 3BNC117, and
10-1074 blocked transmission of HIV-1YU2 under cell contact-
permitting conditions at concentrations similar to those required
for viremic suppression in vivo, each reaching IC50s ≤3 μg/mL and
IC80s ≤15 μg/mL. PG16, which was the least effective of the anti-
bodies in vivo, was unable to reach a consistent IC50 against HIV-
1YU2 in this assay (Fig. S10C andD). These data suggest that highly
potent bNAbs can passively block cell contact-mediated viral
transmission, a property that may be an important determinant of
antibody therapeutic efﬁcacy in hu-mice. Whether other bNAb-
speciﬁc effects, such as ADCC or viral particle clearance, are ad-
ditional mechanisms that contribute to HIV-1 therapy must be
further explored.
Discussion
Monoclonal antibodies have become important components of
the clinical armamentarium in treating malignancies and in-
ﬂammation, but they are rarely used to treat infection.
Combinations of antibodies were tested in HIV-1–infected hu-
mice and humans, but the results were discouraging, leading to
the conclusion that antibodies could not be effective in treating
this disease (11–13). Early experiments in hu-mice showed that
treatment with a mixture of three antibodies had little apparent
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effect on viral load and led to rapid selection for resistant var-
iants (11). In two human trials, antibody therapy following ART
interruption showed only modest effects (12, 13). In one well-
controlled study (12), eight chronically infected patients un-
derwent scheduled ART interruption to determine the baseline
kinetics and magnitude of viral rebound. The same patients were
subsequently treated with a mixture of three bNAbs after ART
was stopped. Only one out of eight showed prolonged viremic
control during bNAb therapy (12).
An important caveat of both human trials is that only one of
the three antibodies used (2G12) exerted any discernible pres-
sure on the virus, and these studies were performed using anti-
bodies that are far less potent than those now available. We have
reinvestigated antibody therapy using recently discovered highly
potent bNAbs in the context of ART interruption in hu-mice. In
contrast to prior studies, our experiments in hu-mice indicate
that immunotherapy can protect against viremic rebound after
discontinuing ART. Surprisingly, even single antibodies were
able to sustain viral suppression when the viral load was initially
lowered with the aid of transient ART.
Experiments in macaques and in mice suggest that a single
injection of a bNAb-encoding AAV can direct long-term ex-
pression of anti–HIV-1 antibodies and afford durable protection
from HIV-1 challenge (38, 46). Whereas these studies highlight
the utility of such vectors for passive vaccination, we show that
bNAb-encoding AAVs can also be used in the context of HIV-1
therapy in hu-mice. Although it remains to be seen whether the
AAV platform will be useful for long-term antibody therapy in
humans, the idea that antibodies might comprise an inexpensive,
single-shot durable therapeutic should be further explored.
Antibodies may control established HIV-1 infection by a vari-
ety of mechanisms that differ from most ART drugs. These
include, among others, facilitating clearance of viral particles, de-
creasing the half-life of infected cells through effector signaling
(ADCC/ACDVI), inhibiting infection by free virions, and blocking
cell contact-mediated viral spread (as we show in vitro for 45-
46G54W, 3BNC117, and 10-1074). That we observe declining levels
of cell-associated HIV-1 DNA during immunotherapy is consistent
with decreasing infected cell half-life and blocking viral spread,
although additional experiments are required to dissect these
mechanisms further. Because the antiviral mechanisms that
underlie bNAb immunotherapy likely differ from those of ART
drugs, the two modalities may prove complementary when used
in combination, particularly in protocols that attempt viral
eradication.
Hu-mice differ from humans in a number of important ways.
For example, because of size differences the total viral load in
hu-mice, and therefore the viral swarm diversity, is far smaller
than in humans. Moreover, the virologic reservoirs in hu-mice
have not been deﬁned and are likely to differ from those found in
humans. Unlike humans, hu-mice are not immunologically com-
petent. They lack an effective innate immune compartment har-
boring functional effector cells, and they are unable to produce
robust T- or B-cell immune responses. In immune competent
hosts, each of these immunological components might amplify the
effects of bNAb immunotherapy in suppressing HIV-1 infection.
In conclusion, immunotherapy using combinations of broadly
neutralizing antibodies achieves viremic control by reducing both
plasma viral load and cell-associated HIV-1 DNA. In mice
treated initially with ART drugs, combination immunotherapy
also protects against viral rebound after discontinuation of ART.
Furthermore, single bNAbs given either as soluble protein or by
AAV injection can durably sustain viremic control when the viral
load is initially lowered by combining ART and immunotherapy.
Whether these effects will also be seen in HIV-1–nfected indi-
viduals can only be determined in clinical trials.
Materials and Methods
Humanized Mice. NOD Rag1−/−Il2rgnull (NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ)
mice were purchased from The Jackson Laboratory and bred and maintained
at the Comparative Bioscience Center of The Rockefeller University accord-
ing to guidelines established by the Institutional Animal Committee. All
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low or undetectable, with one exception (ID num-
ber 399, viral load shown in red line). Three of 17
mice failed to rebound (viral load >3 × 103 copies
per milliliter).
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Fig. 5. Viral gp120 sequences during and after immunotherapy. (A) Muta-
tions in plasma virus gp120 sequences cloned from mice that escaped anti-
body therapy after ART was stopped (Fig. S6). Each line represents a single
clone; red and green marks as in Fig. 2C. All escape variants suffered
mutations at sites known to confer resistance to the respective antibody
(highlighted in blue vertical shading; bold numbers refer to the HXBc2-
aligned residue). (B) Mutations in gp120 sequences cloned from mice that
rebounded after antibody levels became subtherapeutic did not contain
mutations at sites known to confer resistance, with the exception of ID
number 399 (Fig. S8).
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experiments were performed with authorization from the Institutional Re-
view Board and the Institutional Animal Care and Use Committee at The
Rockefeller University. Hu-mice were produced as described (23). Brieﬂy,
neonatal mice (1–5 d of age) were sublethally irradiated and injected
intrahepatically with puriﬁed CD34+ human hematopoietic stem cells de-
rived from fetal liver tissue.
HIV-1 Infection. Hu-mice were screened at 8 wk of age for reconstitution of
human lymphocytes as earlier described (23). Mice with a measurable human
graft were injected intraperitoneally with infectious HIV-1YU2 and screened
for viremia at 2 to 3 wk postinfection by quantitative reverse-transcriptase
PCR (23).
Antiretroviral Therapy. Individual tablets of tenofovir disproxil-fumarate
(TDF; Gilead Sciences), emtricitabine (FTC; Gilead Sciences), raltegravir (RAL;
Merck), and efavirenz (EFV; Bristol-Myers Squibb) were crushed into ﬁne
powder form using a mortar and pestle and suspended in PBS. ART prepa-
rations were aliquotted into 200-μL doses in sterile Eppendorf tubes and
stored at −20 °C until use. TDF, FTC, RAL, and EFV were administered by daily
oral gavage at 2.46, 1.48, 1.23, and 2.46 mg per mouse, respectively, based
on effective doses reported in the literature (47, 48) or human-to-animal
dose translation studies (49).
Antibody Therapy. Monoclonal preparations of bnAbs were isolated in Tris-
glycine using Protein G Sepharose 4 Fast-Flow (GE Healthcare) from tissue-
culture supernatant of HEK 293T (American Type Culture Collection) or HEK
293E cells transfected with plasmids encoding bnAb heavy- and light-chain
Ig genes then buffer-exchanged with PBS and sterile-ﬁltered using Ultrafree-
CL centrifugal ﬁlters (0.22 μm; Millipore). Puriﬁed IgG (10.5 or 1.0 mg) was
injected s.c. into hu-mice twice per week or as described.
Adeno-Associated Virus Vectors. AAV vectors encoding the bnAbs 3BNC117
and 10-1074 were produced as described (50). Brieﬂy, single-stranded AAV
genomes carrying AAV serotype 2 inverted terminal repeats contained
a human thyroglobulin promoter driving the expression of Ig heavy- and
light-chain genes separated by a furin-2A cleavage motif. Vectors were
packaged with the muscle- and liver-tropic AAV serotype 8 capsid protein
and titered by quantitative PCR (50).
HIV-1 Plasma Viral Load. Viral load was determined using one of twomethods.
Viral loads for Fig. S2 were measured using the Abbott HIV-RealTime assay
on the ABBOTT M2000 platform. HIV was automatically extracted with the
M2000SP using 100–400 μL plasma. In case of lower volumes, these were
diluted with PBS and the calculated numbers were adjusted according to the
dilution. Ampliﬁcation and detection were performed with the ABBOTT
M200RT. For all other experiments, viral load was measured using an in-
house quantitative RT-PCR assay as described (23).
Cell-Associated HIV-1 DNA. Mononuclear cells were isolated from mouse
peripheral blood by Ficoll density gradient, or from peripheral lymph nodes
and spleen by tissue homogenization and cell ﬁltration. Homogenized spleen
samples were brieﬂy subjected to ACK lysis (Gibco) to remove erythrocytes.
Total DNA was isolated using the QIAmp DNA blood mini kit (Qiagen) and
eluted in a volume of 80 μL. Puriﬁed DNA was assayed by quantitative re-
verse-transcriptase PCR using the MX3005P QPCR system (Agilent Technol-
ogies). HIV-1–speciﬁc primers and the probe targeting the 5′-LTR were
identical to those used for viral load quantitation. In some cases, a second set
of HIV-1–speciﬁc primers targeting a highly conserved region in pol were
used because they permitted an approximately ﬁvefold higher sensitivity
(forward primer 5′-TAATGGCAGCAATTTCACCA-3′, reverse primer 5′- GAA-
TGCCAAATTCCTGCTTGA-3′, internal probe 5′-/5HEX/CCCACCAAC/ZEN/ARG-
CRGCCTTAACTG/3IABkFQ/-3′). To measure the number of cells in each sample,
extracted samples were assayed in separate reactions for human CCR5 genomic
DNA using the forward primer 5′-GTTGGACCAAGCTATGCAGGT-3′ and reverse
primer 5′-AGAAGCGTTTGGCAATGTGC-3′ with the internal probe 5′-/5HEX/
TTGGGATGA/ZEN/CGCACTGCTGCATCAACCCCA/3IABkFQ/-3′. All quantitative
PCR (qPCR) reactions contained 25ul AmpliTaq Gold PCR master mix (Applied
Biosystems), puriﬁed DNA extract, and nuclease-free water up to 50ul, with the
following primer and probe concentrations: 450nM forward and reverse pri-
mers with 125nM probe (HIV-1 assays); 150nM forward and reverse primers
with 41.5nM probe (CCR5 assay). When necessary, puriﬁed DNA extract was
diluted ﬁvefold in nuclease-free water before qPCR analysis. Reference samples
contained an equal mixture of two plasmids, one encoding HIV-1YU2 and an-
other encoding human CCR5, at 5 × 105 plasmid copies each. The lower limit of
detection for both HIV-1 qPCR assays was found at 2.8 HIV-1 DNA copies per
reaction, corresponding to 56 copies per sample for the LTR-speciﬁc primers
and 12 copies per sample for the pol-speciﬁc primers. The lower limit of de-
tection for the CCR5 qPCR assay was 5.8 copies per reaction, corresponding to
58 cells per sample (based on two copies per cell).
Cell-Associated HIV-1 RNA. Total RNA was isolated from a sample volume
equivalent to that used for extraction of cellular HIV DNA, using the QIAmp
MinElute Virus Spin Kit (Qiagen) in combination with the Qiagen RNase-free
DNase kit and eluted in a volume of 50 μL. RNA was quantiﬁed by quanti-
tative RT-PCR, as was done for viral load. Cell-associated HIV-1 RNA was
reported as RNA copies per 106 human cells based on the ratio of HIV-1 RNA
copies per sample to CCR5 genomic DNA copies per equivalent sample
measured in DNA extract.
Antibody Levels. Total and gp120-speciﬁc human IgG1 levels were measured
from mouse plasma by ELISA as described (23).
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Fig. 6. AAV-directed immunotherapy. (A) HIV-1YU2–infected hu-mice were
treated ﬁrst with ART for 5 d and then with ART plus biotinylated 10-1074
antibody for 16 d (10-1074:bio, 0.5 mg twice per week s.c.). ART was then
terminated and 10-1074:bio continued for an additional 12 d. Mice with viral
loads below the limit of detection (solid blue or red symbols/lines) 12 d after
stopping ART were injected with 2.5 × 1011 genomic copies of a 10-1074–
expressing AAV (AAV10-1074) and passive 10-1074:bio was stopped. Viral loads
were monitored for an additional 67 d. Only one of seven mice escaped AAV10-
1074 therapy, ID number 683. Open symbols/dashed lines, mice above the limit
of viral load detection 12 d after stopping ART; green line, as in Fig. 1A. (B)
Individual mice treated with AAV10-1074. Each graph represents a single mouse.
Blue or red lines/symbols, viral load; yellow lines/symbols, plasma 10-1074
concentration measured by gp120-speciﬁc anti-human IgG1 ELISA. Asterisks
reﬂect the time point at which 10-1074:bio was no longer detectable on
a gp120-speciﬁc anti-biotin ELISA. (C) Mutations in gp120 sequences cloned
from the one mouse that escaped AAV10-1074. Each line represents a single
clone; red and green marks as in Fig. 2C. Consensus mutations were found at
two residues in the 10-1074 binding site (highlighted in blue vertical shading;
bold numbers refer to the HXBc2-aligned residue). (D) Pseudovirus neutrali-
zation by 10-1074 of HIV-1YU2 control andmutant virus frommouse ID number
683 that escaped 10-1074 immunotherapy.
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HIV-1 Genome Sequencing. Viral sequencing for the HIV-1 env gene encoding
gp120 was performed as described (23).
Pseudovirus Neutralization. Antibody neutralization testing of pseudoviruses
carrying the env sequences of HIV-1 isolates from hu-mice was performed by
TZM-bl assay as described (23). Pseudovirus molecular clones were generated
by insertion of env sequences cloned from HIV-1 infected hu-mice into the
KpnI/MfeI restriction sites replacing the sequence for wild-type YU2 in the
pSVIIIenv pseudovirus vector used previously (23).
Statistical Analysis. Statistical analyses were performed using GraphPad Prism
5.0a for Mac OS X.
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